Gene Therapy Of The Human Retina Stocks List

	Symbol	Grade	Name	% Change
	FDMT	F	4D Molecular Therapeutics, Inc.	-2.50
	ADVM	F	Adverum Biotechnologies, Inc.	5.04

Related Industries: Biotechnology

Symbol	Grade	Name	Weight
IDNA	F	iShares Genomics Immunology and Healthcare ETF	0.41
SBIO	C	ALPS Medical Breakthroughs ETF	0.31
BBC	F	Virtus LifeSci Biotech Clinical Trials ETF	0.31
IWC	B	iShares Microcap ETF	0.14
XBI	D	SPDR S&P Biotech ETF	0.12

Compare ETFs

Compare BBC to IWC Compare IDNA to SBIO Compare SBIO to IWC

Date	Stock	Title
Nov 21	FDMT	4D Molecular initiated by Morgan Stanley at underweight
Nov 20	ADVM	Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nov 18	ADVM	Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients
Nov 18	ADVM	Adverum Reports Positive Ixo-vec Data for Wet Age-Related Macular Degeneration; Shares Rise Pre-Bell
Nov 18	ADVM	Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements

Gene Therapy Of The Human Retina: Gene therapy of the human retina is a form of gene therapy that involves introducing healthy genes into the cells of the retina in order to treat or prevent certain diseases or disorders of the eye. This type of therapy is used to treat conditions such as retinitis pigmentosa, age-related macular degeneration, and Leber congenital amaurosis. The goal of gene therapy is to replace the defective gene with a healthy gene, allowing the cells of the retina to function normally.